|
1
|
Early Breast Cancer Trialist Group
(EBCTCG). Effect of chemotherapy and hormonal therapy for early
breast cancer on recurrence and 15-year survival: an overview of
the randomized trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
|
|
2
|
Hortobagyi GN: Anthracyclines in the
treatment of cancer: an overview. Drugs. 54(Suppl 4): 1–7.
1997.
|
|
3
|
Von Hoff D, Layard M, Basa P, Davcis HL,
von Hoff AL, Rozencweig M and Muggia FM: Risk factors for
doxorubicin-induced congestive heart failure. Ann Inter Med.
91:710–717. 1979.PubMed/NCBI
|
|
4
|
Swain S, Whaley FS and Ewer MS: Congestive
heart failure in patients treated with doxorubicin: a retrospective
analysis of three trials. Cancer. 97:2869–2879. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pai VB and Nahata MC: Cardiotoxicity of
chemotherapeutic agents: incidence, treatment and prevention. Drug
Saf. 22:263–302. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Balmer C and Valley AW: Basic principles
of cancer treatment and cancer chemotherapy. Pharmacotherapy: A
Pathophysiology Approach. 3rd edition. Di Piro JT, Talbert RL, Yee
GC, et al: Appleton and Lange; Stanford: pp. 2403–2465. 1997
|
|
7
|
Waterhouse DN, Tardi PG, Mayer Ld and
Balli MB: A comparison of liposomal formulation of doxorubicin with
drug administered in free form: changing toxicity profiles. Drug
Saf. 24:903–920. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maluf FC and Spriggs D: Anthracyclines in
the treatment of gynecologic malignancies. Gynecol Oncol. 85:18–31.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gabizon AA: Liposomal anthracyclines.
Hematol Oncol Clin North Am. 8:431–450. 1994.PubMed/NCBI
|
|
10
|
Rivera E: Liposomal anthracyclines in
metastatic breast cancer: Clinical update. Oncologist. 8(Suppl 3):
3–9. 2003. View Article : Google Scholar
|
|
11
|
Androulakis N, Kouroussis C, Mavroudis D,
Kakolyris S, Souglakos J, Agelaki S, Kalbakis K, Malas K, Pallis A,
Samonis G and Georgoulias V: Phase I study of weekly paclitaxel and
liposomal doxorubicin in patients with advanced solid tumours. Eur
J Cancer. 38:1992–1997. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Perez AT, Domenech GH, Frankel C and Vogel
CL: Pegylated liposomal doxorubicin (Doxil) for metastatic breast
cancer: the Cancer Research Network, Inc. experience Cancer Invest.
20(Suppl 2): 22–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rivera E, Valero V, Arun B, Royce M,
Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L and Hortobagyi
GN: Phase II study of pegylated liposomal doxorubicin in
combination with gemcitabine in patients with metastatic breast
cancer. J Clin Oncol. 21:3249–3254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fabi A, Ferretti G, Papaldo P, Salesi N,
Ciccaresi M, Lo russo V, Carlini P, Carpino A, Mottolese M,
Cianciulli AM, Giannarelli D, Sperduti I, Felici A and Cognetti F:
Pegylated liposomal doxorubicin in combination with gemcitabine: a
phase II study in anthracyclines-naïve and anthracyclines
pretreated metastatic breast cancer patients. Cancer Chemother
Pharmacol. 57:615–623. 2006.
|
|
15
|
Gebbia V, Mauceri G, Fallica G, Borsellino
N, Tirrito ML, Testa A, Varvara F, Colombo A and Ferrera P:
Pegylated liposomal doxorubicin in combination with vinorelbine in
metastatic breast carcinoma. Oncology. 63:23–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ardavanis A, Mavroudis D, Kalbakis K,
Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N,
Kouroussis C, Agelaki S and Geogoulias V: Pegylated liposomal
doxorubicin with vinorelbine as salvage treatment in pretreated
patients with advanced breast cancer: a multicentre phase phase II
study. Cancer Chemother Pharmacol. 58:742–748. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Overmoyer B, Silverman P, Holder LW,
Tripathy D and Henderson IC: Pegylated liposomal doxorubicin and
cyclophophamide as first line therapy for patients with metastatic
or recurrent breast cancer. Clin Cancer. 6:150–157. 2005.PubMed/NCBI
|
|
18
|
Vandenberg TA, Trudeau M, Provencher L,
Panasci LC, Yelle L, Rayson D, Latreille J, Clemons M, Giroux M and
Pouliot J: Pegylated liposomal doxorubicin (PLD) with
cyclophosphamide (c) as 1st-line chemotherapy for metatstatic
breast cancer (MBC) patients previously treated with adjuvant
anthracyclines. J Clin Oncol. 24:106272006.
|
|
19
|
Rigatos SK, Tsavdaridis D, Athananasiadis
A, Stathopoulos JG and Stathopoulos GP: Paclitaxel and liposomal
doxorubicin (Caelyx) combination in advanced breast cancer
patients: A phase II study. Oncol Rep. 10:1817–1819.
2003.PubMed/NCBI
|
|
20
|
Simoncini E, Ferrari VD, Amoroso V,
Valcamonico F, Grisanti S, Vassalli L, Marpicati P, Montini E,
Rangoni G and Marini G: Bi-weekly administration of pegylated
liposomal doxorubicin plus paclitaxel in metastatic breast cancer
(MBC) patients: a phase II study. J Clin Oncol. 23:8442005.
|
|
21
|
Vorobiof DA, Rapoport BL, Chasen MR,
Slabber C, McMichael G, Eek R and Mohammed C: First line therapy
with paclitaxel (Taxol) and pegylated liposomal doxorubicin
(Caelyx) in patients with metastatic breast cancer: a multicentre
phase II study. Breast. 13:219–226. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rossi D, Baldelli AM, Casadei V, Fedeli
SL, Alessandroni P, Catalano V, Giordani P, Ceccolini M, Graziano F
and Catalano G: Neoadjuvant chemotherapy with low dose of pegylated
liposomal doxorubicin plus weekly paclitaxel in operable and
locally advanced breast cancer. Anti-Cancer Drugs. 19:733–737.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alexopoulos A, Karamouzis MV, Stavrinides
H, Ardavanis A, Kandilis K, Stavrakakis J, Georganta C and Rigatos
G: Phase II study of pegylated liposomal doxorubicin (Caelyx) and
docetaxel as first line treatment in metastatic breast cancer. Ann
Oncol. 15:891–895. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Morabito A, Gattuso D, Stani SC, Fanelli
M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale
S, Mariani L and Gasperini G: Safety and activity of the
combination of pegylated liposomal doxorubicin and weekly docetaxel
in advanced breast cancer. Breast Cancer Res Treat. 86:249–257.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sparano JA, Makhson AN, Semiglazov VF, et
al: Pegylated liposomal doxorubicin plus docetaxel improves time to
progression without additive cardiotoxicity compared with docetaxel
monotherapy in patients with advanced breast cancer previously
treated with neoadjuvant-adjuvant anthracycline therapy: results
from randomized phase III study. J Clin Oncol. 27:4522–4529.
2009.
|
|
26
|
De la Fouchardiere, Largillier R, Goubely
Y, Hardy-Bessard AC, Slama B, Cretin J, Orfeuvre H, Paraiso D,
Bachelot T and Pujade-Lauraine E: Docetaxel and pegylated liposomal
doxorubicin combination as first-line therapy for metastatic breast
cancer patients: results of the phase II GINECO trial CAPYTTOLE.
Ann Oncol. 20:1959–1963. 2009.PubMed/NCBI
|
|
27
|
Vogel CL: Salvage chemotherapy of breast
cancer. Semin Oncol. 21:19–24. 1996.
|
|
28
|
Holmes FA, Walters RS, Theriault RL,
Buzdar AU, Frye DK, Hortobagyi GN, Forman AD, Newton LK and Raber
MN: Phase II trial of Taxol, an active drug in the treatment of
metastatic breast cancer. J Natl Cancer Inst. 83:1797–1805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Seidman AD, Hudis C, Albanel J, Tong W,
Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J
and Norton L: Dose-dense therapy with weekly-1-hour paclitaxel
infusion in the treatment of metastatic breast cancer. J Clin
Oncol. 16:3353–3361. 1998.PubMed/NCBI
|
|
30
|
Perez EA, Irwin DH, Patel R, Vogel CL and
Kirshner J: A large phase II trial of paclitaxel administered as a
weekly one hour infusion in patients with metastatic breast cancer.
Proc ASCO. 18:1261999.
|
|
31
|
Loffler TM: Is there a place for
‘dose-dense’ weekly schedules of the taxoids? Sem Oncol. 25(Suppl
12): 32–34. 1998.
|
|
32
|
Verrill MW, Lee J, Cameron DA, Agrawal R,
Cole Ferrigan E and Yellowlees A: Anglo-Celtic IV: first results of
a UK National Cancer Research Network randomized phase III
pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in
patients with locally advanced or metastatic breast cancer (ABC). J
Clin Oncol. 25:LBA10052007.
|
|
33
|
Coleman RE, Biganzoli L, Canney P, Dirix
L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C
and Piccart M: A randomised phase II study of two different
schedules of pegylated liposomal doxorubicin in metastatic breast
cancer (EORTC 10993). Eur J Cancer. 42:882–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Safra T, Muggia F, Jeffers S, Tsao-Wei DD,
Groshen S, Lyass O, Henderson R, Berry G and Gabizon A: Pegylated
liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in
patients reaching or exceeding cumulative doses of 500
mg/m2. Ann Oncol. 11:1029–1033. 2000. View Article : Google Scholar
|
|
35
|
O’Brien MER, Wigler N, Inbar M, Rosso R,
Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP,
Orlandi F, Mellars L, Alland L and Tendler C: Reduced cardiac
toxicity and comparable efficacy in a phase III trial of pegylated
liposomal doxorubicin HCL (Caelyx/Doxil) versus conventional
doxorubicin for first-line treatment of metastatic breast cancer.
Ann Oncol. 15:440–449. 2004.
|
